Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women will be confirmed as postmenopausal (either natural or surgical) based on cessation of menses for \>1 year.~* Ability to provide informed consent~* Baseline brachial flow-mediated dilation (FMD) \< 6%Δ (rationale: non-invasive screening to ensure exclusion of subjects with exceptionally high baseline endothelial function.~* Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 2 min, climb 10 stairs)~* Willing to accept random assignment to condition~Exclusion Criteria:~* Current smoking~* Having past or present alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders~* Body mass index (BMI) \>40 kg/m2 (FMD measurements can be inaccurate in severely obese patients)~* Chronic clinical diseases (e.g., coronary artery/peripheral artery/cerebrovascular diseases, diabetes, chronic kidney disease requiring dialysis, neurological disorders or diseases that may affect motor/cognitive functions \[multiple sclerosis, Parkinson's disease, polio, Alzheimer's disease, dementia or other brain diseases of aging\]), except hypertension and hyperlipidemia~* Regular vigorous aerobic/endurance exercise (\>3 vigorous bouts/week).~* Not weight stable in the prior 3 months (\>2 kg weight change) or unwilling to remain weight stable throughout study (rationale: recent weight change or weight loss can influence vascular function.~* Current treatment or recent cessation (\< 3 mo) of hormone replacement therapy~* Moderate or severe peripheral artery disease (ankle-brachial index \<0.7).~* A graded exercise test will be performed by all subjects, if there is physician concern or an adverse event, the subject will not participate in a maximal oxygen consumption (VO2max) test (this will be determined in accordance with stated contraindications for exercise testing provided by the American Heart Association).~* Thyroid disease that is not controlled by medications or \<3 month's use of a particular medication and/or dosage (uncontrolled thyroid diseases are associated with alterations in vascular function).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- MitoQ (Type: EXPERIMENTAL): MitoQ, 20 mg per day for six weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, inert excipient, one time per day for six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).